Catalyst

Slingshot members are tracking this event:

MediciNova (MNOV) Presents Interim Data from Phase 1b/2a Trial Assessing MN-166 in Amyotrophic Lateral Sclerosis (ALS) at the 27th International Symposium on ALS/MND

Source Link:
http://www.nasdaq.com/press-release/medicinova-announces-exploratory-interim-clinical-outcomes-data-from-clinical-trial-of-mn166-20161209-00088

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
MNOV
100%
SIGN ME UP
I want to vote! LOG ME IN
Now!
Slingshot Insights Explained
JOIN FOR FREE TODAY
Catalyst Date
Occurred on:
Dec 09, 2016
Related Projects Image

  • Don’t see a project related to the catalyst you care about?

Related Keywords Interim Data, Phase 1b/2a, Mn-166, Amyotrophic Lateral Sclerosis, Als, 27th International Symposium On Als/mnd
About Us
Media Center
Connect with Us
© 2024 Slingshot Insights. All rights reserved.